Clinical Trials
6 trialsNCT00054639 2014-05-28
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017589 2014-01-06
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00024440 2014-01-06
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00049192 2013-06-04
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004862 2013-02-01
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00060112 2013-01-25
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated